Literature DB >> 16707957

Increase in circulating bone marrow progenitor cells after myocardial infarction.

Daniel M Spevack1, Salvatore Cavaleri, Alexander Zolotarev, Leonard Liebes, Giorgio Inghirami, Paul A Tunick, Itzhak Kronzon.   

Abstract

BACKGROUND: Most circulating blood cells expressing the marker CD34 are bone marrow progenitor cells. These cells differentiate into cardiomyocytes, endothelial and smooth muscle cells after myocardial infarction in vivo. Mobilization of bone marrow progenitor cells into the peripheral blood after myocardial infarction may supply these cells to the heart. Rise in CD34+ cell concentrations following myocardial infarction would support the existence of myocardial-initiated mobilization.
METHODS: Serial measurements of circulating CD34+ cells were made in 42 consecutive patients presenting with first ST-elevation myocardial infarction. Measurement of serum concentrations of monocyte chemoattractant protein-1, stromal derived factor-1, hepatocyte growth factor, interleukin-17 and thrombopoietin was also performed. Samples were drawn on day 1 after myocardial infarction, and on days 4, 8 and 12. Levels of CD34+ cells and cytokines were also measured in 15 controls.
RESULTS: By day 8, the mean concentration of CD34+ cells rose by 74% above mean control level of 2527 cells/ml, and 41% above day 1 mean (P=0.02). This rise was sustained on day 12 (P=0.05). On day 1, there was a 9.3-fold rise in hepatocyte growth factor above the control level of 589 pg/ml (P=0.002). Hepatocyte growth factor levels declined from the day 1 mean of 6061 to 1485 pg/ml on day 12 (P=0.002). No significant change in stromal derived factor-1, interleukin-17, monocyte chemoattractant protein-1 and thrombopoietin was observed. Elevations in CD34+ cells and hepatocyte growth factor were not related to infarction size as estimated on echocardiography.
CONCLUSIONS: Elevation in the concentration of circulating CD34+ cells after myocardial infarction suggests that myocardial initiated bone marrow progenitor cell mobilization exists in humans. The cytokines studied in our protocol are not likely to play a direct role in bone marrow progenitor cell mobilization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707957     DOI: 10.1097/00019501-200606000-00004

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  5 in total

Review 1.  Very small embryonic-like stem cells: biology and therapeutic potential for heart repair.

Authors:  Ewa K Zuba-Surma; Wojciech Wojakowski; Mariusz Z Ratajczak; Buddhadeb Dawn
Journal:  Antioxid Redox Signal       Date:  2011-05-05       Impact factor: 8.401

2.  Homing of stem cells to ischemic myocardium.

Authors:  Sharven Taghavi; Jon C George
Journal:  Am J Transl Res       Date:  2013-05-24       Impact factor: 4.060

3.  Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction.

Authors:  Ewa K Zuba-Surma; Magdalena Kucia; Buddhadeb Dawn; Yiru Guo; Mariusz Z Ratajczak; Roberto Bolli
Journal:  J Mol Cell Cardiol       Date:  2008-03-04       Impact factor: 5.000

4.  Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair.

Authors:  Ying Dai; Muhammad Ashraf; Shi Zuo; Ryota Uemura; Yan-Shan Dai; Yigang Wang; Husnain Kh Haider; Tingyu Li; Meifeng Xu
Journal:  J Mol Cell Cardiol       Date:  2007-12-07       Impact factor: 5.000

5.  Myocardial Ischemia and Mobilization of Circulating Progenitor Cells.

Authors:  Muhammad Hammadah; Ayman Samman Tahhan; Ibhar Al Mheid; Kobina Wilmot; Ronnie Ramadan; Bryan R Kindya; Heval M Kelli; Wesley T O'Neal; Pratik Sandesara; Samaah Sullivan; Zakaria Almuwaqqat; Malik Obideen; Naser Abdelhadi; Ayman Alkhoder; Pratik M Pimple; Oleksiy Levantsevych; Kareem H Mohammed; Lei Weng; Laurence S Sperling; Amit J Shah; Yan V Sun; Brad D Pearce; Michael Kutner; Laura Ward; J Douglas Bremner; Jinhee Kim; Edmund K Waller; Paolo Raggi; David Sheps; Viola Vaccarino; Arshed A Quyyumi
Journal:  J Am Heart Assoc       Date:  2018-02-10       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.